



# Drug Discovery

An International Journal

## FDA Approved Drugs – February 2016

Vidhya V

### Publication History

Received: 12 May 2016

Accepted: 25 May 2016

Published: April-June 2016

### Citation

Vidhya V. FDA Approved Drugs – February 2016. *Drug Discovery*, 2016, 11(28), 23-24

### Publication License



© The Author(s) 2016. Open Access. This article is licensed under a Creative Commons Attribution License 4.0 (CC BY 4.0).

### General Note



Article is recommended to print as digital color version in recycled paper.

### BRIVIACT (BRIVARACETAM)

**Company:** UCB; Approved by February 2016

**Specific Treatments:** partial onset seizures related to epilepsy

### General Information

Briviact is specifically indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. It is supplied in three formulations: tablet, oral solution and injection for intravenous administration. The recommended starting dosage is 50 mg twice daily (100 mg per day). Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day).

Vidhya V,

FDA Approved Drugs – February 2016,

*Drug Discovery*, 2016, 11(28), 23-24,

© The Author(s) 2016. Open Access. This article is licensed under a Creative Commons Attribution License 4.0 (CC BY 4.0)

**Mechanism of Action**

Briviact (brivaracetam) displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect. However, the precise mechanism by which Briviact exerts its anticonvulsant activity is not known.

**Side Effects**

Adverse effects associated with the use of Briviact may include: somnolence/sedation, dizziness, fatigue, nausea/vomiting